Alnylam Pharmaceuticals (ALNY) PT Raised to $360 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Kostas Biliouris raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $360.00 while maintaining a Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
